

# Kazunari Tateishi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9403424/kazunari-tateishi-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17  
papers

84  
citations

6  
h-index

8  
g-index

18  
ext. papers

137  
ext. citations

3.2  
avg, IF

2.62  
L-index

#	Paper	IF	Citations
17	Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.. <i>Cancer Management and Research</i> , <b>2022</b> , 14, 427-435	3.6	0
16	Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy.. <i>Thoracic Cancer</i> , <b>2022</b> ,	3.2	1
15	Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series.. <i>Case Reports in Oncology</i> , <b>2021</b> , 14, 1561-1566	1	0
14	Prognostic implication of erector spinae muscles in non-small-cell lung cancer patients treated with immuno-oncology combinatorial chemotherapy. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2857-2864	3.2	1
13	Clinical utility of the C-reactive protein:albumin ratio in non-small cell lung cancer patients treated with nivolumab. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 603-612	3.2	6
12	The Role of Immune-Related Adverse Events in Prognosis and Efficacy Prediction for Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: A Retrospective Clinical Analysis. <i>Oncology</i> , <b>2021</b> , 99, 271-279	3.6	5
11	Prognostic value of the geriatric nutritional risk index among patients with previously treated advanced non-small cell lung cancer who subsequently underwent immunotherapy. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 1366-1372	3.2	10
10	Successful recovery from critical COVID-19 pneumonia with extracorporeal membrane oxygenation: A case report. <i>Respiratory Medicine Case Reports</i> , <b>2020</b> , 30, 101113	1.2	5
9	Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study. <i>Oncologist</i> , <b>2020</b> , 25, e668-e674	5.7	7
8	Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy. <i>Lung Cancer</i> , <b>2020</b> , 148, 122-128	5.9	3
7	Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1578-1586	3.2	10
6	Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute. <i>Chemotherapy</i> , <b>2019</b> , 64, 129-137	3.2	12
5	Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1078-1085	3.2	3
4	The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1805-1811	3.2	2
3	Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study. <i>Oncologist</i> , <b>2018</b> , 23, 1210-1217	5.7	9
2	Two patients with TAFRO syndrome exhibiting strikingly similar anterior mediastinal lesions with predominantly fat attenuation on chest computed tomography. <i>Respiratory Investigation</i> , <b>2017</b> , 55, 176-180	3.4	7
1	Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study. <i>Respiratory Investigation</i> , <b>2016</b> , 54, 462-467	3.4	3

